MRFR is the Leading Brand in The Research Company who Recently Published Ventilator-associated pneumonia (VAP) Market Research Reports which includes Study of growth, Regional Analysis, Top Industry Players Formation, Major Drivers, Upcoming Trends and Forecast to 2023.
Ventilator-associated pneumonia is a type of lung infection caused to patients who are on ventilators. Ventilator-associated pneumonia is caused mainly due to lung disease, neurologic disease, and trauma to critically ill persons. Diagnosing VAP requires aggressive surveillance combined with the radiographic examination, bedside examination, and microbiologic examinations of respiratory secretions. Growing Intensive Care Unit Admissions due to rising prevalence of respiratory diseases, rising number of ICU beds and high incidence of traumatic injuries provides favorable backgrounds for the market to grow. According to CDC in 2013, there were 2.8 million traumatic brain injury visits to emergency department and hospitals. The emergency department visits of brain injury patients increased by 47% from 2007. Thus, increasing incidence of TBI drives the growth of the market. Furthermore, increasing geriatric population is likely to fuel the market to grow. According to the U.S. Census Bureau in 2015, 47.8 million people were 65 years or older, and in 2060, 98.2 million are expected to be 65 years or older. Such increasing trend in the geriatric population provides favorable backgrounds for the market to grow.
Get Sample Copy @ https://www.marketresearchfuture.com/sample_request/1377
However, factors such as expensive diagnostic tests, high ventilator charges, inappropriate reimbursement scenario, risks associated with ventilators are expected to restrict the market growth during the forecast period.
On the basis of region, the global Ventilator-associated pneumonia market is segmented into the Americas, Europe, Asia Pacific, and the Middle East and Africa. The Americas is sub-segmented into North America and South America. The North American region is further segmented into the U.S. and Canada. The European region is divided into two, namely, Western Europe and Eastern Europe. Western Europe is further classified into Germany, Italy, France, the U.K., Spain, and the rest of Western Europe. The Asia Pacific region is sub-segmented into Japan, China, India, Australia, the Republic of Korea, and the rest of Asia Pacific. The Middle Eastern and African region is sub-segmented into the United Arab Emirates, Saudi Arabia, Oman, Kuwait, Qatar, and the rest of the Middle East and Africa.
The global Ventilator-associated pneumonia market is segmented on the basis of diagnosis, mode of treatment, and end-user. The Ventilator-associated pneumonia market, by diagnosis categorized into Clinical Examination, Radiological Examination, Microbiological Analysis and others. Microbiological Analysis is further sub-segmented into Blood and pleural fluid cultures, Nonquantitative or semi-quantitative airway sampling and Quantitative cultures of airway specimens. Mode of treatment segment is segmented into Homecare, Hospital care, and others. On the basis of end-user, the market is segmented into Hospitals & Clinics, Research centers, Ambulatory Care Centers and Emergency Medical Services (EMS).
Regional Market Summary
The Ventilator-associated pneumonia market is dominated by North America owing to the rising geriatric population within the region. The U.S. Census Bureau projected that in 2060, 19.7 million would be of age 85 or older. This influences the growth of this market in this region.
Asia Pacific was projected to be the fastest growing region for the global Ventilator-associated pneumonia market in 2017. The rising geriatric population, increasing healthcare expenditure and growing respiratory disorders in Asia is expected to drive market growth in this region. According to The Asian Development Bank (ADB), the geriatric population in Asia is estimated to reach 923 million by 2050. Thus, this provides favorable backgrounds for the Ventilator-associated pneumonia market to grow.
It is estimated that Europe stood second in the global Ventilator-associated pneumonia market owing to increasing prevalence of lung diseases. According to European respiratory society, more than 50% of deaths are due to lung diseases. Thus, increasing prevalence of lung diseases in this region influences the growth of this market in this region.
The Middle East and Africa holds the least share in the global Ventilator-associated pneumonia market due to the presence of stringent government policies, poor economies, under-developed healthcare infrastructure and low penetration of healthcare services, especially within the African region.
Some of the key players for the global Ventilator-associated pneumonia market Merck & Co., Inc. (U.S.), Adenium Biotech ApS (Denmark), AstraZeneca (UK), MedImmune (US), Nabriva Therapeutics AG (Austria) and other.
Browse Complete 110 Pages Premium Research Report Enabled with Respective Tables and Figures @ https://www.marketresearchfuture.com/reports/ventilator-associated-pneumonia-vap-market-1377
Detailed Table of Contents:
Chapter 1. Report Prologue
Chapter 2. Market Introduction
2.2 Scope Of The Study
2.2.1 Research Objective
Chapter 3. Research Methodology
3.2 Primary Research
3.3 Secondary Research
3.4 Market Size Estimation
Chapter 4. Market Dynamics
4.5 Macroeconomic Indicators
4.6 Technology Trends & Assessment
Chapter 5. Market Factor Analysis
5.1 Porter’s Five Forces Analysis
5.1.1 Bargaining Power Of Suppliers
5.1.2 Bargaining Power Of Buyers
5.1.3 Threat Of New Entrants
5.1.4 Threat Of Substitutes
5.1.5 Intensity Of Rivalry
Send and Enquiry @ https://www.marketresearchfuture.com/enquiry/1377
Market Research Future (MRFR), enable customers to unravel the complexity of various industries through Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.
Market Research Future
Office No. 528, Amanora Chambers
Magarpatta Road, Hadapsar,
Pune – 411028
Phone: +1 646 845 9312